Paraneoplastic neurological syndromes

Orphanet Journal of Rare Diseases

Volumn 2, Issue 1, 2007, Pages

  Honnorat, Jérôme ^a   Antoine, Jean Christophe ^b  

^a UNIVERSITÉ LYON 1   (France)

^b SERVICE DE NEUROLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CEREBELLAR ATAXIA; DERMATOMYOSITIS; EATON LAMBERT SYNDROME; ENCEPHALOMYELITIS; HUMAN; INTESTINE PSEUDOOBSTRUCTION; OPSOCLONUS MYOCLONUS SYNDROME; PARANEOPLASTIC NEUROPATHY; RETINA DISEASE; REVIEW; SENSORY DYSFUNCTION; STIFF MAN SYNDROME; SYNDROME;

CEREBELLAR ATAXIA; DERMATOMYOSITIS; ENCEPHALOMYELITIS; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; LAMBERT-EATON MYASTHENIC SYNDROME; LIMBIC ENCEPHALITIS; OPSOCLONUS-MYOCLONUS SYNDROME; PARANEOPLASTIC POLYNEUROPATHY; RETINAL DISEASES; SENSATION DISORDERS; STIFF-PERSON SYNDROME; SYNDROME;

EID: 34249074265     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-2-22     Document Type: Review

References (76)

1. Posner JB, Furneaux HM: Paraneoplastic syndromes. Res Publ Assoc Res Nerv Ment Dis 1990, 68:187-219.
2. Darnell RB, Posner JB: Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003, 349:1543-1454.
3. Vianello M, Vitaliani R, Pezzani R, Nicolao P, Betterle C, Keir G, Thompson EJ, Tavolato B, Scaravilli F, Giometto B: The spectrum of antineuronal autoantibodies in a series of neurological patients. J Neurol Sci 2004, 220:29-36.
4. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler Ch, Verschuuren JJ, Vincent A, Voltz R: Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004, 75:1135-1140.
5. Scheid R, Honnorat J, Delmont E, Urbach H, Biniek R: A new antineuronal antibody in a case of paraneoplastic limbic encephalitis associated with breast cancer. J Neurol Neurosurg Psychiatry 2004, 75:338-340.
6. Sculier JP, Feld R, Evans WK, DeBoer G, Shepherd FA, Payne DG, Pringle JF, Yeoh JL, Quirt IC, Curtis JE, et al.: Neurologic disorders in patients with small cell lung cancer. Cancer 1987, 60:2275-2283.
7. Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, Delattre JY: Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000, 68:479-482.
8. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW: Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro-oncol 2004, 6:55-62.
9. Stich O, Graus F, Rasiah C, Rauer S: Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration, J Neuroimmunol 2003, 141:165-169.
10. Alamowitch S, Graus F, Uchuya M, Reñé R, Bescansa E, Delattre JY: Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997, 120:923-928.
11. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J: Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000, 123:1481-1494.
12. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF: Antibodies to a subpopulation of glial cells and a 66 kD developmental protein in patients with paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatr 1996, 61:270-278.
13. Antoine JC, Absi L, Honnorat J, Boulesteix JM, de Brouker T, Vial C, Butler M, De Camilli P, Michel D: Antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. Arch Neurol 1999, 56:172-177.
14. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR: Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004, 127:1831-1844.
15. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor MN, Palace J: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004, 127:701-712.
16. Peterson K, Rosenblum MK, Posner JB: Paraneoplastic cerebellar degeneration: a clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
17. Rojas l, Graus F, Keime-Guibert F, Rene R, Delattre JY, Ramon JM, Dalmau J, Posner JB: Long-term clinical outcome of paraneo-plastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000, 55:713-715.
18. Bernal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P, Graus F: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003, 60:230-234.
19. Wiener V, Honnorat J, Pandolfo M, Kentos A, Manto MU: Myorhythmia associated with Hodgkin's lymphoma. J Neurol 2003, 250:1382-1384.
20. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J: Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton mysthenic syndrome. Brain 1997, 120:1279-1300.
21. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA: CRMP-5 neuronal autoantibody: Marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001, 49:146-154.
22. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J: Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology 2004, 62:778-782.
23. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J: Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol 2001, 50:339-348.
24. Shams'ili S, Grefkens J, de Leeuw B, van den Bent M, Hooijkaas H, van der Holt B, Vecht C, Sillevis Smitt P: Paraneoplastic cerebellar degeneration associated with antineuronal antibodies : analysis of 50 patients. Brain 2003, 126:1409-1418.
25. Pranzatelli MR, Tate ED, Wheeler A, Bass N, Gold AP, Griebel ML, Gumbinas M, Heydemann PT, Holt PJ, Jacob P, Kotagal S, Minarcik CJ, Schub HS: Screening for autoantibodies in children with opsoclonus-myoclonus-ataxia. Pediatr Neurol 2002, 27:384-387.
26. Gambini C, Conte M, Bernini G, Angelini P, Pession A, Paolucci P, Donfrancesco A, Veneselli E, Mazzocco K, Tonini GP, Raffaghello L, Dominici C, Morando A, Negri F, Favre A, De Bernardi B, Pistoia V: Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases. Virchows Arch 2003, 442:555-562.
27. Luque FA, Furneaux HM, Ferziger R, Rosenblum MK, Wray SH, Schold SC Jr, Glantz MJ, Jaeckle KA, Biran H, Lesser M, et al.: Anti-Ri: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991, 29:241-251.
28. Pittock SJ, Lucchinetti CF, Lennon VA: Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 2003, 53:580-587.
29. Bataller L, Graus F, Saiz A, Vilchez JJ, Spanish Opsoclonus-Myoclonus Study Group: Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus- myoclonus. Brain 2001, 124:437-443.
30. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J: Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol 2003, 53:347-353.
31. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, Escaramis G, Delattre JY: Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001, 124:1138-1148.
32. Bataller L, Dalmau J: Neuro-ophthalmology and paraneoplastic syndromes. Curr Opin Neurol 2004, 17:3-8.
33. Keltner JL, Thirkill CE, Yip PT: Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases, j Neuroophthalmol 2001, 21:173-187.
34. Shiraga S, Adamus G: Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 2002, 132:72-82.
35. Ohguro H, Nakazawa M: Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 2002, 514:109-124.
36. Alexander KR, Barnes CS, Fishman GA, Pokorny J, Smith VC: Contrast-processing deficits in melanoma-associated retinopathy. Invest Optoholmol Vis Sci 2004, 45:305-310.
37. Milam AH, Saari JC, Jacobson SG, Lubinski WP, Feun LG, Alexander KR: Autoantibodies against retinal bipolar cells in cutaneous melanoma-associated retinopathy. invest Ophthalmol Vis Sci 1993, 34:91-100.
38. de la Sayette V, Bertran F, Honnorat J, Schaeffer S, Iglesias S, Defer G: Paraneoplastic cerebellar syndrome and optic neuritis with anti-CV2 antibodies: clinical response to excision of the primary tumor. Arch Neurol 1998, 55:405-408.
39. Cross SA, Salomao DR, Parisi JE, Kryzer TJ, Bradley EA, Mines JA, Lam BL, Lennon VA: Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-lgG. Ann Neurol 2003, 54:38-50.
40. De Giorgio R, Guerrini S, Barbara G, Stanghellini V, De Ponti F, Corinaldesi R, Moses PL, Sharkey KA, Mawe GM: Inflammatory neuropathies of the enteric nervous system. Gostroenterology 2004, 126:1872-1883.
41. Vernino S, Adamski J, Kryzer TJ, Fealey RD, Lennon VA: Neuronal nicotinic ACh receptor antibody in subacute autonomic neuropathy and cancer-related syndromes. Neurology 1998, 50:1806-1813.
42. Molinuevo JL, Graus F, Serrano C, Rene R, Guerrero A, Ilia I: Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998, 44:976-980.
43. Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine 1992, 71:59-72.
44. Camdessanche JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, Michel D: Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 2002, 125:166-175.
45. O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988, 111:577-596.
46. Newsom-Davis J: Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 2004, 160:177-180.
47. Fukuda T, Motomura M, Nakao Y, Shiraishi H, Yoshimura T, Iwanaga K, Tsujihata M, Eguchi K: Reduction of P/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome. Ann Neurol 2003, 53:21-28.
48. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A: P/ Q type calcium-channel antibodies in paraneoplastic cere-bellar degeneration with lung cancer. Neurology 2002, 59:764-766.
49. Folli F, Solimena M, Cofiell R, Austoni M, Tallini G, Fassetta G, Bates D, Cartlidge N, Bottazzo GF, Piccolo G, et al.: Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993, 328:546-551.
50. Petzold GC, Marcucci M, Butler MH, van Landeghem FK, Einhaupl KM, Solimena M, Valdueza JM, De Camilli P: Rhabdomyolysis and paraneoplastic stiff-man syndrome with amphiphysin autoimmunity. Ann Neurol 2004, 55:286-290.
51. Wabbels BK, Elflein H, Lorenz B, Kolling G: Bilateral tonic pupils with evidence of anti-hu antibodies as a paraneoplastic manifestation of small cell lung cancer. Ophthalmologica 2004, 218:141-143.
52. Georgian-Smith D, Ellis GK, Kraft GH: Amphiphysin paraneoplastic syndrome: a delayed diagnosis of breast carcinoma. Breast J 2003, 9:316-318.
53. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans S, Felson D: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96-100.
54. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E: Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992, 326:363-367.
55. Honnorat J, Cartalat-Carel S: Advances in paraneoplastic neurological syndromes. Curr Opin Oncol 2004, 16:614-620.
56. Roberts WK, Darnell RB: Neuroimmunology of the paraneoplastic neurological degenerations. Curr Opin Immunol 2004, 16:616-622.
57. Kim YI: Passively transferred Lambert-Eaton syndrome in mice receiving purified IgG. Muscle Nerve 1986, 9:523-530.
58. Sakai K, Kitagawa Y, Saiki S, Saiki M, Hirose G: Effect of a paraneoplastic cerebellar degeneration-associated neurol protein on B-myb promoter activity. Neurobiol Dis 2004, 15:529-533.
59. Ricard D, Rogemond V, Charrier E, Aguera M, Bagnard D, Belin MF, Thomasset N, Honnorat J: Isolation and expression pattern of human Unc-33-like phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): coexistence with Ulip2/ CRMP2 in Sema3a- sensitive oligodendrocytes. J Neurosci 2001, 21:7203-7214.
60. Okano HJ, Park WY, Corradi JP, Darnell RB: The cytoplasmic Purkinje onconeural antigen cdr2 down-regulates c-Myc function: implications for neuronal and tumor cell survival. Genes Dev 1999, 13:2087-2097.
61. Tanaka K, Ding X, Tanaka M: Effects of antineuronal antibodies from patients with paraneoplastic neurological syndrome on primary-cultured neurons. J Neurol Sci 2004, 217:25-30.
62. Graus F, Illa I, Agusti M, Ribalta T, Cruz-Sanchez F, Juarez C: Effect of intraventricular injection of anti-Purkinje cell antibody (anti-Yo) in a guinea pig model, J Neurol Sci 1991, 106:82-87.
63. Albert ML, Austin L, Darnell RB: Detection and treatment of activated T cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol 2000, 47:9-17.
64. Plonquet A, Garcia-Pons F, Fernandez E, Philippe C, Marquet J, Rouard H, Delfau-Larue MH, Kosmatopoulos K, Lemonnier F, Farcet JP, Gherardi RK, Langlade-Demoyen P: Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HMD mouse and human. J Neuroimmunol 2003, 142:93-100.
65. Albert ML, Darnell JC, Bender A, Francisco LM, Bhardwaj N, Darnell RB: Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Not Med 1998, 4:1321-1324.
66. Sutton IJ, Steele J, Savage CO, Winer JB, Young LS: An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies. J Neuroimmunol 2004, 150:98-106.
67. Posner JB: Neurologic complications of cancer Philadelphia: FA. Davis Company; 1995.
68. Chartrand-Lefebvre C, Howarth N, Grenier P, Keime F, Orcel B, Beigelman C: Association of small cell lung cancer and the anti-Hu paraneoplastic syndrome: radiological and CT findings. AJR Am J Roentgenol 1998, 170:1513-1517.
69. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J: FDG-PET improves tumor detection in patients with paraneoplastic neurological syndromes. Brain 2004, 127:2331-2338.
70. Linke R, Schroeder M, Helmberger T, Voltz R: Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurology 2004, 63:282-286.
71. Antoine JC, Cinotti L, Tilikete C, Bouhour F, Camdessanche JP, Confavreux C, Vighetto A, Renault-Mannel V, Michel D, Honnorat J: [18 F] Fluorodeoxyglucose positon emission tomography in the diagnosis of cancer in patients with paraneoplastic neurological syndrome and anti-Hu antibodies. Ann Neurol 2000, 48:105-108.
72. Rees JH, Hain SF, Johnson MR, Hughes RA, Costa DC, Ell PJ, Keir G, Rudge P: The role of [18 F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Brain 2001, 124:2223-2231.
73. Luchinetti CF, Kimmel DW, Lennon V: Paraneoplastic and oncologic profiles of patients seropositive for type I antineuronal nuclear antibodies. Neurology 1998, 50:652-657.
74. Cartalat-Carel S, Camdessanche JP, Ricard D, et al.: The paraneoplastic neurological syndrome associated with anti-CV2 (anti-CRMPS) antibodies is different from that of anti-Hu antibodies [abstract]. Neurology 2004, 62(Suppl 5):A476-A477.
75. Widdess-Walsh P, Tavee JO, Schuele S, Stevens GH: Response to intravenous immunoglobulin in anti-Yo associated paraneoplastic cerebellar degeneration: case report and review of the literature, J Neurooncol 2003, 63:187-190.
76. PNS Euro network [http://www.pnseuronet.org]